Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review

• Published in: Expert opinion on therapeutic patents Vol. 21; no. 7; p. 1109
• Main Authors: Zask, Arie, Verheijen, Jeroen C, Richard, David J
• Format: Journal Article
• Language: English
• Published: England 01.07.2011
• Subjects: Adenosine Triphosphate - metabolism; Animals; Antineoplastic Agents - pharmacology; Binding, Competitive; Drug Delivery Systems; Drug Design; Humans; Neoplasms - drug therapy; Neoplasms - physiopathology; Patents as Topic; Phosphatidylinositol 3-Kinases - antagonists & inhibitors; TOR Serine-Threonine Kinases - antagonists & inhibitors
• ISSN: 1744-7674
• DOI: 10.1517/13543776.2011.584871

The mammalian target of rapamycin (mTOR) is a protein kinase and a key component of the PI3K/Akt/mTOR signaling pathway, and is deregulated in half of all human cancers. Rapamycin and its analogs (rapalogs) are allosteric inhibitors of one functional mTOR complex, mTORC1, and are clinically proven therapeutic agents for the treatment of certain cancers. However, rapalogs mainly partially inhibit mTORC1, while ATP competitive inhibitors suppress both mTORC1 and mTORC2, and therefore may offer advantages in the clinic. Recently, small-molecule inhibitors have entered clinical trials that are mTOR-selective or dual mTOR/PI3K inhibitors. This review focuses on ATP-competitive mTOR inhibitors that have appeared in the patent literature in 2010. Many inhibitors with new structural motifs have been discovered as well as inhibitors that are related to previously disclosed structures. This review endeavors to put into perspective the diverse structural elements that make up these compounds. Patent applications are covered that include either selective mTOR inhibitors or dual mTOR/PI3K inhibitors. The PI3K/mTOR signaling pathway is an exciting target for the development of pharmaceuticals to treat cancer and other diseases, due to the unique combination of a clinically and commercially validated pathway approach (i.e., rapalogs), combined with a biological rationale for further increased efficacy (i.e., ATP-competitive inhibitors). With the number of candidate drugs currently in development or at earlier stages of the drug discovery pipeline, we are bound to see small-molecule inhibitors reach pivotal trials, and hopefully the market, in the near future.